Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial with PH-762 and AgonOx’s Tumor Infiltrating Lymphocytes to Treat Solid Tumors

The initial Phase 1 clinical trial will assess safety and therapeutic benefit from the administration of Phio’s PH-762 treated “double positive” CD8 tumor infiltrating lymphocyte in patients with melanoma and other advanced solid tumors.